The CHMP [1](#Fn1){ref-type="fn"} has released its highlights from its July meeting − including recommending approval of eleven medicines and negative recommendations for two medicines, says the EMA.

Firstly, the agency highlighted that the **Dapivirine** Vaginal Ring \"*is the eleventh medicine recommended by EMA under EU Medicines for all (EU-M4All), a mechanism that allows the CHMP to assess and give opinions on medicines that are intended for use in countries outside the EU*\".

The other medicines recommended for approval by the CHMP were:

**belantamab mafodotin** (Blenrep) for use in adult patients with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, a proteasome inhibitor and a CD-38 monoclonal antibody;**crizanlizumab** (Adakveo) for prevention of recurrent vaso-occlusive crises in patients with sickle cell disease;**amikacin** (Arikayce liposomal) for the treatment of non-tuberculous mycobacterial lung infections caused by *Mycobacterium avium* complex in adults with limited treatment options who do not have cystic fibrosis;**avapritinib** (Ayvakyt) for unresectable or metastatic gastrointestinal stromal tumours harbouring the platelet-derived growth factor receptor alpha D842V mutation;**acalabrutinib** (Calquence) for treatment of chronic lymphocytic leukaemia;**filgotinib** (Jyseleca) for treatment of rheumatoid arthritis;**bupivacaine/meloxicam** (Zynrelef) for treatment of postoperative pain;the biosimilar **bevacizumab** medicine (Equidacent) for the treatment of various carcinomas; andtwo generic medicines − **arsenic trioxide** (Arsenic trioxide medac) for the treatment of acute promyelocytic leukaemia, and **fampridine** (Fampridine Accord) that is intended for use in adults with multiple sclerosis with walking disability.

Conversely, the CHMP recommended against approval of two medicines: **tagraxofusp** (Elzonris) that was expected to be used for treatment of a rare and aggressive blood cancer (blastic plasmacytoid dendritic cell neoplasm), and **emapalumab** (Gamifant) that was expected to be used to treat primary haemophagocytic lymphohistiocytosis in children aged \<18 years.

In addition, there were recommendations for therapeutic indication extensions for nine medicines, as well as a recommendation to change **lidocaine/prilocaine** (Fortacin) from a prescription to a non-prescription medicine.

The outcomes of reviews for other medicines were also discussed − including generic medicines tested by Panexcell Clinical Laboratories in India, and **trabectedin** (Yondelis).

Furthermore, the CHMP has started a review of results from the RECOVERY study arm that used **dexamethasone** in the treatment of hospitalised patients with COVID-19.

Finally, the CHMP mentioned that initial marketing authorisation applications for **abicipar pegol** (Rayoqta) and **aripiprazole** (Abilify MyCite) have been withdrawn.

CHMP = Committee for Medicinal Products for Human Use
